Skip to main content

About GEP-NETs

Important Safety Information

WARNINGS AND PRECAUTIONS

  • Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure and is associated with an increased risk for cancer...

Indication

LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
References: 1. National Center for Advancing Translational Sciences. Neuroendocrine tumor. Accessed April 8, 2021. https://rarediseases.info.nih.gov/diseases/13445/neuroendocrine-tumor 2. National Cancer Institute. Neuroendocrine tumor. Accessed April 8, 2021. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/neuroendocrine-tumor 3. American Society of Clinical Oncology. Neuroendocrine Tumors: Introduction. Accessed June 23, 2021. https://www.cancer.net/cancer-types/neuroendocrine-tumors/introduction 4. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342. 5. US Food and Drug Administration. Rare Diseases at FDA. Accessed June 23, 2021. https://www.fda.gov/patients/rare-diseases-fda 6. Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629-5638. 7. Sackstein PE, O’Neil DS, Neuget AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45(4):249-258. 8. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794-1803. 9. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 10. Campana D, Tomassetti P. Incidence, epidemiology, aetiology and staging, classification, clinical presentation/signs and symptoms, diagnosis, staging procedures/investigation. In: PET/CT in Neuroendocrine Tumors, Clinicians’ Guides to Radionuclide Hybrid Imaging. 1st ed. Springer International; 2016:1-5. 11. Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2017;3(1):43-53. 12. Vinik AI, Woltering EA, Warner RRP, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713-734.